7月16日 - ** 药物开发商 Sarepta Therapeutics SRPT.O股价在延时交易中大涨 50%，至 27.60 美元
** 该公司表示将裁员36% (link)，约500个工作岗位，每年可节省约4亿美元。
** 截至2024年12月31日，该公司共有1372名员工 (link) - SEC文件
** 美国食品和药物管理局（FDA）将对公司的基因疗法 Elevidys 增加黑框警告，警告其存在严重的肝脏风险
** 公司任命 Ryan Wong 为首席财务官
** 股价今年以来下跌了 85
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.